

Supplementary Figure 1. PRISMA flow diagram of study selection.

a) Risk of bias graph



b) Risk of bias summary



Supplementary Figure 2. Risk of bias assessment.

a) Overall symptoms



b) All-cause discontinuation



c) Depressive symptoms

Study or Subgroup	Weight	Std. Mean Difference IV, Random, 95% CI	Year
2.1.1 All studies			
Girgis_52wk (H) 2011	11.4%	−0.42 [−0.82, −0.02]	2011
Savitz_26wk (Pal) 2015	26.9%	−0.06 [−0.32, 0.20]	2015
Robinson_12wk (R) 2015	23.4%	−0.27 [−0.55, 0.01]	2015
Pagsberg_12wk (Q) 2017	11.4%	0.04 [−0.36, 0.44]	2017
Liemburg_9wk (R) 2018	2.6%	−0.30 [−1.14, 0.54]	2018
Gomez-Revuelta_3yr (R+Q+O+Z+H) 2020	24.4%	−0.17 [−0.44, 0.10]	2020
Subtotal (95% CI)	**100.0%**	**−0.17 [−0.31, −0.04]**	
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 3.79$, df = 5 (P = 0.58); $I^2 = 0\%$			
Test for overall effect: Z = 2.48 (P = 0.01)			
2.1.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	23.7%	−0.41 [−0.71, −0.11]	2013
Robinson_12wk (R) 2015	27.5%	−0.27 [−0.55, 0.01]	2015
Savitz_8wk (Pal) 2015	31.0%	−0.07 [−0.33, 0.19]	2015
Pagsberg_12wk (Q) 2017	14.5%	0.04 [−0.36, 0.44]	2017
Liemburg_9wk (R) 2018	3.5%	−0.30 [−1.14, 0.54]	2018
Subtotal (95% CI)	**100.0%**	**−0.20 [−0.35, −0.04]**	
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 4.43$, df = 4 (P = 0.35); $I^2 = 10\%$			
Test for overall effect: Z = 2.44 (P = 0.01)			
2.1.3 Long-term studies			
Girgis_52wk (H) 2011	19.0%	−0.42 [−0.82, −0.02]	2011
Savitz_26wk (Pal) 2015	42.3%	−0.06 [−0.32, 0.20]	2015
Gomez-Revuelta_3yr (R+Q+O+Z+H) 2020	38.7%	−0.17 [−0.44, 0.10]	2020
Subtotal (95% CI)	**100.0%**	**−0.17 [−0.35, 0.01]**	
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 2.17$, df = 2 (P = 0.34); $I^2 = 8\%$			
Test for overall effect: Z = 1.87 (P = 0.06)			



d) Prolactin levels

Study or Subgroup	Weight	Std. Mean Difference IV, Random, 95% CI	Year
1.2.1 All studies			
Crespo-Facorro_52wk (Q+Z) 2013	21.6%	−0.19 [−0.53, 0.15]	2013
Robinson_12wk (R) 2015	22.4%	−1.01 [−1.31, −0.72]	2015
Savitz_26wk (Pal) 2015	22.4%	−0.85 [−1.14, −0.55]	2015
Takekita_12wk (Per) 2015	15.3%	−0.59 [−1.22, 0.05]	2015
Pagsberg_12wk (Q) 2017	18.4%	−0.02 [−0.51, 0.47]	2017
Subtotal (95% CI)	**100.0%**	**−0.55 [−0.94, −0.16]**	
Heterogeneity: $Tau^2 = 0.15$; $Chi^2 = 21.04$, df = 4 (P = 0.0003); $I^2 = 81\%$			
Test for overall effect: Z = 2.76 (P = 0.006)			
1.2.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	21.5%	−0.42 [−0.76, −0.08]	2013
Savitz_8wk (Pal) 2015	22.1%	−1.16 [−1.47, −0.85]	2015
Takekita_12wk (Per) 2015	15.6%	−0.59 [−1.22, 0.05]	2015
Robinson_12wk (R) 2015	22.3%	−1.01 [−1.31, −0.72]	2015
Pagsberg_12wk (Q) 2017	18.5%	−0.02 [−0.51, 0.47]	2017
Subtotal (95% CI)	**100.0%**	**−0.67 [−1.07, −0.26]**	
Heterogeneity: $Tau^2 = 0.17$; $Chi^2 = 22.16$, df = 4 (P = 0.0002); $I^2 = 82\%$			
Test for overall effect: Z = 3.23 (P = 0.001)			
1.2.3 Long-term studies			
Crespo-Facorro_52wk (Q+Z) 2013	49.2%	−0.19 [−0.53, 0.15]	2013
Savitz_26wk (Pal) 2015	50.8%	−0.85 [−1.14, −0.55]	2015
Subtotal (95% CI)	**100.0%**	**−0.52 [−1.17, 0.12]**	
Heterogeneity: $Tau^2 = 0.19$; $Chi^2 = 8.25$, df = 1 (P = 0.004); $I^2 = 88\%$			
Test for overall effect: Z = 1.59 (P = 0.11)			



e) Triglyceride levels

Study or Subgroup	Weight	Std. Mean Difference IV, Random, 95% CI	Year
2.3.1 All studies			
Zhang_52wk (Z+Pal) 2012	7.6%	−0.18 [−0.84, 0.49]	2012
Zhang_8wk (Q+O) 2014	16.2%	−0.45 [−0.79, −0.11]	2014
Takekita_12wk (Per) 2015	8.2%	−0.35 [−0.98, 0.28]	2015
Savitz_26wk (Pal) 2015	19.0%	−0.27 [−0.55, 0.01]	2015
Robinson_12wk (R) 2015	18.9%	−0.11 [−0.39, 0.17]	2015
Pagsberg_12wk (Q) 2017	13.1%	−0.64 [−1.07, −0.21]	2017
Vazquez-Bourgon_3yr (Q+Z) 2020	17.0%	0.22 [−0.10, 0.54]	2020
Subtotal (95% CI)	**100.0%**	**−0.23 [−0.45, −0.02]**	
Heterogeneity: $Tau^2 = 0.04$; $Chi^2 = 13.31$, df = 6 (P = 0.04); $I^2 = 55\%$			
Test for overall effect: Z = 2.13 (P = 0.03)			
2.3.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	18.0%	−0.18 [−0.51, 0.15]	2013
Zhang_8wk (Q+O) 2014	17.1%	−0.45 [−0.79, −0.11]	2014
Takekita_12wk (Per) 2015	5.8%	−0.35 [−0.98, 0.28]	2015
Savitz_8wk (Pal) 2015	23.8%	−0.16 [−0.44, 0.12]	2015
Robinson_12wk (R) 2015	23.7%	−0.11 [−0.39, 0.17]	2015
Pagsberg_12wk (Q) 2017	11.6%	−0.64 [−1.07, −0.21]	2017
Subtotal (95% CI)	**100.0%**	**−0.27 [−0.42, −0.11]**	
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 6.06$, df = 5 (P = 0.30); $I^2 = 18\%$			
Test for overall effect: Z = 3.35 (P = 0.0008)			
2.3.3 Long-term studies			
Zhang_52wk (Z+Pal) 2012	19.2%	−0.18 [−0.84, 0.49]	2012
Savitz_26wk (Pal) 2015	42.3%	−0.27 [−0.55, 0.01]	2015
Vazquez-Bourgon_3yr (Q+Z) 2020	38.5%	0.22 [−0.10, 0.54]	2020
Subtotal (95% CI)	**100.0%**	**−0.06 [−0.42, 0.29]**	
Heterogeneity: $Tau^2 = 0.06$; $Chi^2 = 5.18$, df = 2 (P = 0.07); $I^2 = 61\%$			
Test for overall effect: Z = 0.35 (P = 0.73)			



f) Total cholesterol levels

Study or Subgroup	Weight	Std. Mean Difference IV, Random, 95% CI	Year
2.4.1 All studies			
Zhang_52wk (Z+Pal) 2012	7.3%	0.65 [−0.16, 1.46]	2012
Zhang_8wk (Q+O) 2014	16.3%	−0.24 [−0.58, 0.10]	2014
Savitz_26wk (Pal) 2015	17.9%	−0.32 [−0.60, −0.04]	2015
Takekita_12wk (Per) 2015	10.0%	−0.01 [−0.63, 0.61]	2015
Robinson_12wk (R) 2015	17.8%	−0.39 [−0.67, −0.11]	2015
Pagsberg_12wk (Q) 2017	13.9%	−0.82 [−1.26, −0.38]	2017
Vazquez-Bourgon_3yr (Q+Z) 2020	16.7%	0.18 [−0.14, 0.50]	2020
Subtotal (95% CI)	**100.0%**	**−0.20 [−0.47, 0.06]**	
Heterogeneity: $Tau^2 = 0.08$; $Chi^2 = 19.80$, df = 6 (P = 0.003); $I^2 = 70\%$			
Test for overall effect: Z = 1.49 (P = 0.14)			
2.4.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	18.8%	0.04 [−0.27, 0.35]	2013
Zhang_8wk (Q+O) 2014	17.6%	−0.24 [−0.58, 0.10]	2014
Savitz_8wk (Pal) 2015	20.6%	−0.23 [−0.51, 0.05]	2015
Takekita_12wk (Per) 2015	8.7%	−0.01 [−0.63, 0.61]	2015
Robinson_12wk (R) 2015	20.5%	−0.39 [−0.67, −0.11]	2015
Pagsberg_12wk (Q) 2017	13.7%	−0.82 [−1.26, −0.38]	2017
Subtotal (95% CI)	**100.0%**	**−0.28 [−0.49, −0.06]**	
Heterogeneity: $Tau^2 = 0.04$; $Chi^2 = 11.24$, df = 5 (P = 0.05); $I^2 = 56\%$			
Test for overall effect: Z = 2.49 (P = 0.01)			
2.4.3 Long-term studies			
Zhang_52wk (Z+Pal) 2012	20.3%	0.65 [−0.16, 1.46]	2012
Savitz_26wk (Pal) 2015	40.8%	−0.32 [−0.60, −0.04]	2015
Vazquez-Bourgon_3yr (Q+Z) 2020	38.9%	0.18 [−0.14, 0.50]	2020
Subtotal (95% CI)	**100.0%**	**0.07 [−0.41, 0.55]**	
Heterogeneity: $Tau^2 = 0.13$; $Chi^2 = 8.50$, df = 2 (P = 0.01); $I^2 = 76\%$			
Test for overall effect: Z = 0.29 (P = 0.77)			



g) Glucose levels

Study or Subgroup	Weight	Std. Mean Difference IV, Random, 95% CI	Year
2.5.1 All studies			
Zhang_52wk (Z+Pal) 2012	10.0%	1.01 [0.42, 1.60]	2012
Zhang_8wk (Q+O) 2014	15.8%	-0.14 [-0.48, 0.20]	2014
Savitz_26wk (Pal) 2015	17.5%	-0.29 [-0.56, -0.02]	2015
Takekita_12wk (Per) 2015	9.4%	0.04 [-0.58, 0.66]	2015
Robinson_12wk (R) 2015	17.3%	-0.38 [-0.66, -0.10]	2015
Pagsberg_12wk (Q) 2017	13.8%	-0.12 [-0.54, 0.30]	2017
Vazquez-Bourgon_3yr (Q+Z) 2020	16.2%	-0.04 [-0.36, 0.28]	2020
Subtotal (95% CI)	**100.0%**	**-0.06 [-0.31, 0.20]**	
Heterogeneity: $Tau^2 = 0.08$; $Chi^2 = 19.27$, df = 6 (P = 0.004); $I^2 = 69\%$			
Test for overall effect: Z = 0.44 (P = 0.66)			
2.5.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	18.8%	-0.21 [-0.53, 0.11]	2013
Zhang_8wk (Q+O) 2014	16.4%	-0.14 [-0.48, 0.20]	2014
Robinson_12wk (R) 2015	24.0%	-0.38 [-0.66, -0.10]	2015
Savitz_8wk (Pal) 2015	24.9%	-0.21 [-0.49, 0.07]	2015
Takekita_12wk (Per) 2015	4.9%	0.04 [-0.58, 0.66]	2015
Pagsberg_12wk (Q) 2017	11.0%	-0.12 [-0.54, 0.30]	2017
Subtotal (95% CI)	**100.0%**	**-0.22 [-0.35, -0.08]**	
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 2.35$, df = 5 (P = 0.80); $I^2 = 0\%$			
Test for overall effect: Z = 3.09 (P = 0.002)			
2.5.3 Long-term studies			
Zhang_52wk (Z+Pal) 2012	28.4%	1.01 [0.42, 1.60]	2012
Savitz_26wk (Pal) 2015	36.4%	-0.29 [-0.56, -0.02]	2015
Vazquez-Bourgon_3yr (Q+Z) 2020	35.3%	-0.04 [-0.36, 0.28]	2020
Subtotal (95% CI)	**100.0%**	**0.17 [-0.43, 0.76]**	
Heterogeneity: $Tau^2 = 0.23$; $Chi^2 = 15.39$, df = 2 (P = 0.0005); $I^2 = 87\%$			
Test for overall effect: Z = 0.55 (P = 0.58)			



h) Sedation

Study or Subgroup	Weight	Risk Ratio M-H, Random, 95% CI	Year
1.6.1 All studies			
Girgis_52wk (H) 2011	9.0%	0.81 [0.36, 1.81]	2011
Takekita_12wk (Per) 2015	3.8%	0.92 [0.23, 3.58]	2015
Robinson_12wk (R) 2015	19.7%	0.94 [0.62, 1.44]	2015
Savitz_8wk (Pal) 2015	9.9%	0.99 [0.47, 2.11]	2015
Pagsberg_12wk (Q) 2017	33.3%	1.09 [0.97, 1.23]	2017
Gomez-Revuelta_3yr (R+Q+O+Z+H) 2020	24.3%	0.71 [0.51, 0.98]	2020
Subtotal (95% CI)	**100.0%**	**0.91 [0.69, 1.21]**	
Total events			
Heterogeneity: $Tau^2 = 0.06$; $Chi^2 = 12.30$, df = 5 (P = 0.03); $I^2 = 59\%$			
Test for overall effect: Z = 0.63 (P = 0.53)			
1.6.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	16.9%	0.68 [0.37, 1.26]	2013
Robinson_12wk (R) 2015	26.9%	0.94 [0.62, 1.44]	2015
Takekita_12wk (Per) 2015	4.6%	0.92 [0.23, 3.58]	2015
Pagsberg_12wk (Q) 2017	51.7%	1.09 [0.97, 1.23]	2017
Subtotal (95% CI)	**100.0%**	**0.96 [0.71, 1.30]**	
Total events			
Heterogeneity: $Tau^2 = 0.04$; $Chi^2 = 5.63$, df = 3 (P = 0.13); $I^2 = 47\%$			
Test for overall effect: Z = 0.27 (P = 0.79)			
1.6.3 Long-term studies			
Girgis_52wk (H) 2011	11.8%	0.81 [0.36, 1.81]	2011
Savitz_8wk (Pal) 2015	13.4%	0.99 [0.47, 2.11]	2015
Gomez-Revuelta_3yr (R+Q+O+Z+H) 2020	74.8%	0.71 [0.51, 0.98]	2020
Subtotal (95% CI)	**100.0%**	**0.75 [0.57, 0.99]**	
Total events			
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.69$, df = 2 (P = 0.71); $I^2 = 0\%$			
Test for overall effect: Z = 2.01 (P = 0.04)			



i) Anticholinergic use

Study or Subgroup	Weight	Risk Ratio M-H, Random, 95% CI	Year
1.7.1 All studies			
Savitz_26wk (Pal) 2015	16.5%	0.99 [0.64, 1.55]	2015
Robinson_12wk (R) 2015	18.1%	0.81 [0.54, 1.20]	2015
Takekita_12wk (Per) 2015	3.4%	0.92 [0.23, 3.58]	2015
Wang_7wk (R+Q+O+Z) 2017	8.3%	2.12 [0.96, 4.68]	2017
Pagsberg_12wk (Q) 2017	5.3%	3.32 [1.16, 9.47]	2017
Cheng (R+O) 2019	22.5%	1.54 [1.16, 2.06]	2019
Gomez-Revuelta_3yr (R+Q+O+Z) 2020	25.9%	1.46 [1.19, 1.78]	2020
Subtotal (95% CI)	**100.0%**	**1.32 [1.01, 1.72]**	
Total events			
Heterogeneity: Tau² = 0.06; Chi² = 14.05, df = 6 (P = 0.03); I² = 57%			
Test for overall effect: Z = 2.05 (P = 0.04)			
1.7.2 Short-term studies			
Crespo-Facorro_12wk (Q+Z) 2013	16.4%	1.69 [0.85, 3.38]	2013
Robinson_12wk (R) 2015	24.7%	0.81 [0.54, 1.20]	2015
Takekita_12wk (Per) 2015	6.6%	0.92 [0.23, 3.58]	2015
Pagsberg_12wk (Q) 2017	9.9%	3.32 [1.16, 9.47]	2017
Wang_7wk (R+Q+O+Z) 2017	14.2%	2.12 [0.96, 4.68]	2017
Cheng (R+O) 2019	28.2%	1.54 [1.16, 2.06]	2019
Subtotal (95% CI)	**100.0%**	**1.45 [0.98, 2.15]**	
Total events			
Heterogeneity: Tau² = 0.12; Chi² = 12.02, df = 5 (P = 0.03); I² = 58%			
Test for overall effect: Z = 1.87 (P = 0.06)			
1.7.3 Long-term studies			
Wang_26wk (R+O) 2013	11.0%	1.85 [0.82, 4.20]	2013
Savitz_26wk (Pal) 2015	28.5%	0.99 [0.64, 1.55]	2015
Gomez-Revuelta_3yr (R+Q+O+Z) 2020	60.5%	1.46 [1.19, 1.78]	2020
Subtotal (95% CI)	**100.0%**	**1.34 [1.00, 1.79]**	
Total events			
Heterogeneity: Tau² = 0.03; Chi² = 3.06, df = 2 (P = 0.22); I² = 35%			
Test for overall effect: Z = 1.97 (P = 0.05)			



j) Akathisia

Study or Subgroup	Weight	Risk Ratio M-H, Random, 95% CI	Year
1.8.1 All studies			
Maat (R) 2014	0.7%	9.92 [0.55, 178.45]	2014
Savitz_26wk (Pal) 2015	8.2%	0.69 [0.31, 1.54]	2015
Robinson_12wk (R) 2015	17.4%	1.52 [0.90, 2.55]	2015
Takekita_12wk (Per) 2015	5.3%	2.44 [0.88, 6.82]	2015
Pagsberg_12wk (Q) 2017	43.5%	1.39 [1.08, 1.79]	2017
Wang_7wk (R+Q+O+Z) 2017	8.5%	2.12 [0.96, 4.68]	2017
Gomez-Revuelta_3yr (R+Q+O+Z) 2020	16.4%	1.24 [0.72, 2.12]	2020
Subtotal (95% CI)	**100.0%**	**1.42 [1.11, 1.81]**	
Total events			
Heterogeneity: Tau² = 0.02; Chi² = 7.25, df = 6 (P = 0.30); I² = 17%			
Test for overall effect: Z = 2.79 (P = 0.005)			
1.8.2 Short-term studies			
Maat (R) 2014	0.4%	9.92 [0.55, 178.45]	2014
Takekita_12wk (Per) 2015	3.5%	2.44 [0.88, 6.82]	2015
Robinson_12wk (R) 2015	13.8%	1.52 [0.90, 2.55]	2015
Pagsberg_12wk (Q) 2017	58.4%	1.39 [1.08, 1.79]	2017
Juncal-Ruiz_6wk (R+Q+O+Z) 2017	17.9%	1.39 [0.88, 2.20]	2017
Wang_7wk (R+Q+O+Z) 2017	5.9%	2.12 [0.96, 4.68]	2017
Subtotal (95% CI)	**100.0%**	**1.49 [1.23, 1.80]**	
Total events			
Heterogeneity: Tau² = 0.00; Chi² = 3.88, df = 5 (P = 0.57); I² = 0%			
Test for overall effect: Z = 4.04 (P < 0.0001)			
1.8.3 Long-term studies			
Savitz_26wk (Pal) 2015	36.5%	0.69 [0.31, 1.54]	2015
Gomez-Revuelta_3yr (R+Q+O+Z) 2020	63.5%	1.24 [0.72, 2.12]	2020
Subtotal (95% CI)	**100.0%**	**1.00 [0.57, 1.74]**	
Total events			
Heterogeneity: Tau² = 0.05; Chi² = 1.42, df = 1 (P = 0.23); I² = 30%			
Test for overall effect: Z = 0.01 (P = 0.99)			



Supplementary Figure 3. Forest plots of comparisons of aripiprazole with D_2R antagonists for main findings. H: haloperidol; O: olanzapine; Pal: paliperidone; Per: perospirone; Q: quetiapine; R: risperidone; Z: ziprasidone. For plots i) and j), haloperidol trials were removed for a more meaningful comparison of aripiprazole with second-generation D_2 antagonists.

Supplementary Table 1. Meta-regression analysis of the association of covariates with overall symptom reduction and all-cause discontinuation

	N	Estimate	SE	*t*	95% CI	*p*
Overall symptom reduction						
Sample size	14	0.00	0.00	-0.42	-0.01 to 0.00	0.679
Percent open label	13	-0.19	0.29	-0.67	-0.83 to 0.45	0.519
Study year	14	-0.01	0.05	-0.19	-0.13 to 0.10	0.851
Age	13	0.02	0.02	1.21	-0.02 to 0.06	0.250
Percent male	13	0.00	0.01	-0.18	-0.02 to 0.02	0.859
Trial duration	14	-0.01	0.00	-2.69	-0.01 to -0.00	**0.020**
Percent first episode	14	0.22	0.26	0.83	-0.35 to 0.79	0.421
Aripiprazole dose	13	-0.01	0.02	-0.53	-0.06 to 0.04	0.609
Baseline PANSS total	14	-0.02	0.01	-2.30	-0.03 to -0.00	**0.041**
Percent risperidone/olanzapine	14	-0.16	0.30	-0.55	-0.81 to 0.49	0.594
Blinding[a]	13	-0.07	0.15	-0.46	-0.41 to 0.27	0.653
All-cause discontinuation						
Sample size	11	-0.00	0.00	-0.78	-0.01 to 0.00	0.435
Percent open label	11	-0.06	0.29	-0.20	-0.63 to 0.51	0.838
Study year	11	0.01	0.05	0.29	-0.08 to 0.10	0.775
Age	11	-0.01	0.02	-0.34	-0.06 to 0.04	0.736
Percent male	11	-0.00	0.01	-0.36	-0.02 to 0.02	0.717
Trial duration	11	-0.00	0.00	-0.62	-0.01 to 0.00	0.534
Percent first episode	11	0.13	0.30	0.42	-0.46 to 0.71	0.676
Aripiprazole dose	10	-0.02	0.01	-1.46	-0.05 to 0.01	0.146
Baseline PANSS total	11	-0.01	0.01	-1.44	-0.03 to 0.00	0.149
Percent risperidone/olanzapine	11	0.01	0.30	0.03	-0.58 to 0.60	0.974
Blinding[a]	11	-0.04	0.15	-0.26	-0.33 to 0.25	0.796

[a]Open-label, single-blind, and double-blind studies coded as 0, 1, and 2, respectively. D_2R: dopamine D_2 receptor; PANSS: Positive and Negative Syndrome Scale.



Supplementary Figure 4. Funnel plots of a) overall symptom reduction and b) all-cause discontinuation.